Brokerages Set InflaRx N.V. (NASDAQ:IFRX) Target Price at $7.50

InflaRx N.V. (NASDAQ:IFRX) has been given an average recommendation of “Moderate Buy” by the seven research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $7.50.

A number of analysts recently weighed in on the company. Guggenheim increased their price objective on InflaRx from $10.00 to $22.00 and gave the company a “buy” rating in a report on Monday, November 10th. Raymond James Financial reiterated an “outperform” rating on shares of InflaRx in a research report on Wednesday, December 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research note on Monday, December 29th. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of InflaRx in a research report on Tuesday, December 30th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 price objective (down from $5.00) on shares of InflaRx in a research note on Wednesday, December 3rd.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of IFRX. Concurrent Investment Advisors LLC increased its stake in InflaRx by 56.9% in the fourth quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock valued at $53,000 after purchasing an additional 19,200 shares in the last quarter. DCF Advisers LLC acquired a new position in shares of InflaRx during the fourth quarter valued at about $160,000. T3 Companies LLC bought a new position in shares of InflaRx during the 4th quarter worth about $294,000. Cubist Systematic Strategies LLC boosted its position in shares of InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after purchasing an additional 7,616 shares in the last quarter. Finally, Suvretta Capital Management LLC grew its stake in shares of InflaRx by 22.4% in the 4th quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after buying an additional 1,450,000 shares during the period. Institutional investors and hedge funds own 42.39% of the company’s stock.

InflaRx Price Performance

IFRX opened at $0.97 on Monday. InflaRx has a fifty-two week low of $0.71 and a fifty-two week high of $1.94. The company’s 50 day moving average price is $0.95 and its two-hundred day moving average price is $1.16. The firm has a market capitalization of $65.12 million, a price-to-earnings ratio of -1.43 and a beta of 1.48.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.